U.S., May 5 -- ClinicalTrials.gov registry received information related to the study (NCT07564479) titled 'Alpha-Lipoic Acid in Mitigating Cisplatin-Induced Nephrotoxicity' on April 13.
Brief Summary: To assess the nephroprotective efficacy of Alpha-Lipoic Acid in preventing cisplatin-induced nephrotoxicity in oncology patients by monitoring renal function changes
Study Start Date: March 10
Study Type: INTERVENTIONAL
Condition:
Cisplatin Nephrotoxicity
Nephrotoxicity
Intervention:
DRUG: Alpha-Lipoic Acid (ALA)
The intervention under investigation is the administration of oral Alpha-Lipoic Acid (ALA) as an adjunct to standard cisplatin-based chemotherapy.
Recruitment Status: RECRUITING
Sponsor: Minia University
Information provide...